Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Earnings Data
Report Date
Feb 26, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.31Last Year’s EPS
-0.31Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the clinical development of pociredir for sickle cell disease, with promising trial results and a strong financial position. Despite a decrease in cash reserves and continued net losses, the company's achievements and future plans position it well for further advancements.Company Guidance
Encouraging Phase Ib PIONEER Trial Results
Pociredir demonstrated a dose-dependent and clinically meaningful increase in fetal hemoglobin, improvement in key biomarkers of hemolysis, and reduction in vaso-occlusive crises for sickle cell disease patients. Additionally, it was well tolerated with all treatment AEs being grade 1.
Completion of Enrollment in 20mg Cohort
The company completed enrollment in the 20mg dose cohort with 12 evaluable patients. Over-enrollment in both 12mg and 20mg cohorts signals strong enthusiasm from participating physicians.
Strong Financial Position
Fulcrum ended the third quarter of 2025 with $200.6 million in cash, cash equivalents, and marketable securities, providing sufficient runway to fund operations into 2028.
Potential IND Submission
Fulcrum plans to submit an IND for bone marrow failure syndromes by the end of 2025, expanding their therapeutic focus beyond sickle cell disease.
FULC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FULC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 29, 2025 | $10.00 | $9.36 | -6.40% |
Jul 29, 2025 | $7.81 | $7.59 | -2.82% |
May 01, 2025 | $3.85 | $4.38 | +13.77% |
Feb 25, 2025 | $3.70 | $3.70 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Fulcrum Therapeutics (FULC) report earnings?
Fulcrum Therapeutics (FULC) is schdueled to report earning on Feb 26, 2026, Before Open (Confirmed).
What is Fulcrum Therapeutics (FULC) earnings time?
Fulcrum Therapeutics (FULC) earnings time is at Feb 26, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FULC EPS forecast?
FULC EPS forecast for the fiscal quarter 2025 (Q4) is -0.31.